Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir

Clinical Infectious Diseases

Volumn 56, Issue 5, 2013, Pages 718-726

  Hulskotte, Ellen G J ^a   Feng, Hwa Ping ^b   Xuan, Fengjuan ^b   Van Zutven, Marga G J A ^a   Treitel, Michelle A ^b   Hughes, Eric A ^b   O'Mara, Edward ^b   Youngberg, Stephen P ^c   Wagner, John A ^b   Butterton, Joan R ^b  

^a NV ORGANON   (Netherlands)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CELERION   (United States)

Author keywords

atazanavir; boceprevir; darunavir; lopinavir; pharmacokinetics

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR;

ABDOMINAL CRAMP; ADULT; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLURRED VISION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIZZINESS; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG INTERACTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FEMALE; HUMAN; HUMAN EXPERIMENT; JAUNDICE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HEPACIVIRUS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; PYRIDINES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 84873683339     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis968     Document Type: Article

References (28)

1. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33:240-7.
2. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
3. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIVinfected patients: a randomized controlled trial. JAMA 2004; 292:2839-48.
4. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
5. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50:1013-20.
6. Bacon B, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
7. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
8. US Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdole scentGL.pdf. Accessed 25 November 2012.
9. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-20.
10. Liu L, Mugundu GM, Kirby BJ, Samineni D, Desai PB, Unadkat JD. Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. Biopharm Drug Dispos 2012; 33:207-17.
11. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 2010; 268:530-9.
12. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 2010; 40:163-76.
13. VICTRELIS™ (boceprevir) tablets [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp, May 2011.
14. Kaletra™ (lopinavir/ritonavir) tablets [prescribing information]. North Chicago, IL: Abbott Laboratories, April 2012.
15. Prezista™ (darunavir) tablets [prescribing information]. Raritan, NJ: Tibotec Therapeutics, Division of Ortho Biotech Products, June 2006.
16. Reyataz™ (atazanavir sulfate) capsules [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, June 2003.
17. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64:1147-61.
18. Thomas DL, Bartlett JG, Peters MG, Sherman KE, Sulkowski MS, Pham PA. Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012; 54:979-83.
19. Sulkowski M, Pol S, Cooper C. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-coinfected patients: End of treatment (week 48) interim results. Available at: http://retroconfer ence.org/static/ webcasts/2012/. Accessed 25 November 2012.
20. Wenning L, Flexner C, Liu R, et al. Assessment of boceprevir (VICTRELIS ™) pharmacokinetic/pharmacodynamic relationships for sustained viral response (SVR) and occurrence of anemia: results in HCV/HIV coinfected patients and in combined mono-and co-infected patients. In: 63rd Annual Meeting of the American Association for the Study of Liver Disease, 9-13 November 2012, Boston, MA; abstract 707.
21. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
22. European AIDS Clinical Society (EACS). Guidelines: clinical management and treatment of chronic hepatitis B and C coinfection in HIVinfected adults. Available at: http://www.europeanaidsclinicalsociety. org/images/stories/EACS- Pdf/EACSGuidelines-v6.0-English.pdf. Accessed 25 November 2012.
23. de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis 2013; 56:298-304.
24. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions. In: 18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011, Boston, MA.
25. Hammond K, Wolfe P, Burton J, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. Rev Antiviral Ther Infect Dis 2012; 3:17.
26. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42:1048-59.
27. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42:52-60.
28. US Food and Drug Administration. FDA Antiviral Drugs Advisory Committee Meeting, Boceprevir capsules briefing document. 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Com mitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM 252343.pdf. Accessed 25 November 2012.